The lncRNA PCAT29 inhibits oncogenic phenotypes in prostate cancer

Rohit Malik, Lalit Patel, John R. Prensner, Yang Shi, Matthew K. Iyer, Shruthi Subramaniyan, Alexander Carley, Yashar S. Niknafs, Anirban Sahu, Sumin Han, Teng Ma, Meilan Liu, Irfan A. Asangani, Xiaojun Jing, Xuhong Cao, Saravana M. Dhanasekaran, Dan R. Robinson, Felix Y. Feng, Arul M. Chinnaiyan

Research output: Contribution to journalArticle

79 Scopus citations

Abstract

Long noncoding RNAs (lncRNA) have recently been associated with the development and progression of a variety of human cancers. However, to date, the interplay between known oncogenic or tumor-suppressive events and lncRNAs has not been well described. Here, the novel lncRNA, prostate cancer-associated transcript 29 (PCAT29), is characterized along with its relationship to the androgen receptor. PCAT29 is suppressed by DHT and upregulated upon castration therapy in a prostate cancer xenograft model. PCAT29 knockdown significantly increased proliferation and migration of prostate cancer cells, whereas PCAT29 overexpression conferred the opposite effect and suppressed growth and metastases of prostate tumors in chick chorioallantoic membrane assays. Finally, in prostate cancer patient specimens, low PCAT29 expression correlated with poor prognostic outcomes. Taken together, these data expose PCAT29 as an androgen-regulated tumor suppressor in prostate cancer.

Original languageEnglish (US)
Pages (from-to)1081-1087
Number of pages7
JournalMolecular Cancer Research
Volume12
Issue number8
DOIs
Publication statusPublished - Aug 2014
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Molecular Biology
  • Oncology
  • Cancer Research

Cite this

Malik, R., Patel, L., Prensner, J. R., Shi, Y., Iyer, M. K., Subramaniyan, S., ... Chinnaiyan, A. M. (2014). The lncRNA PCAT29 inhibits oncogenic phenotypes in prostate cancer. Molecular Cancer Research, 12(8), 1081-1087. https://doi.org/10.1158/1541-7786.MCR-14-0257